Title |
Hwangryunhaedoktang in adult patients with Atopic Dermatitis: a randomised, double-blind, placebo-controlled, two-centre trial - study protocol
|
---|---|
Published in |
BMC Complementary Medicine and Therapies, August 2011
|
DOI | 10.1186/1472-6882-11-68 |
Pubmed ID | |
Authors |
Nam-Kwen Kim, Dong-Hyo Lee, Hyung-Sik Seo, Seung-Ho Sun, Yong-Leol Oh, Ji-Eun Kim, In-Hwan Yoon, Eun-Sung Seo, Gye-Seon Shim, Christopher Zaslawski |
Abstract |
Atopic Dermatitis is a chronic relapsing eczematous skin disease with increasing prevalence and rising costs. It has a clear impact on a patient's quality of life. Many patients are worried about the use of usual care techniques, such as corticosteroids and antihistamine due to the widespread fear of adverse effects. Complementary and alternative medical approaches have been employed to relieve symptoms of Atopic Dermatitis. Hwangryunhaedoktang is among the most strongly preferred and widely used herbal medicines for Atopic Dermatitis in Korea, as it causes very few serious adverse effects.We aim to establish basic clinical efficacy and safety data for Hwangryunhaedoktang, which is approved as an herbal medication by the Korean Food and Drug Administration, in adult patients with Atopic Dermatitis. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 50 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 5 | 10% |
Student > Doctoral Student | 5 | 10% |
Other | 4 | 8% |
Researcher | 3 | 6% |
Student > Master | 3 | 6% |
Other | 6 | 12% |
Unknown | 24 | 48% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 13 | 26% |
Nursing and Health Professions | 3 | 6% |
Computer Science | 2 | 4% |
Agricultural and Biological Sciences | 1 | 2% |
Unspecified | 1 | 2% |
Other | 5 | 10% |
Unknown | 25 | 50% |